GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Assertio Holdings Inc (NAS:ASRT) » Definitions » Profitability Rank
中文

Assertio Holdings (Assertio Holdings) Profitability Rank

: 4 (As of Dec. 2023)
View and export this data going back to 1997. Start your Free Trial

Assertio Holdings has the Profitability Rank of 4.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Assertio Holdings's Operating Margin % for the quarter that ended in Dec. 2023 was -19.68%. As of today, Assertio Holdings's Piotroski F-Score is 4.


Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Assertio Holdings's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Assertio Holdings Profitability Rank Distribution

For the Drug Manufacturers industry and Healthcare sector, Assertio Holdings's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Assertio Holdings's Profitability Rank falls into.



Assertio Holdings Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Assertio Holdings has the Profitability Rank of 4.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Assertio Holdings's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-6.493 / 32.985
=-19.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Assertio Holdings has an F-score of 4 indicating the company's financial situation is typical for a stable company.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Assertio Holdings Profitability Rank Related Terms

Thank you for viewing the detailed overview of Assertio Holdings's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Assertio Holdings (Assertio Holdings) Business Description

Traded in Other Exchanges
N/A
Address
100 South Saunders Road, Suite 300, Lake Forest, IL, USA, 60045
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
Executives
Daniel A. Peisert director, officer: President & CEO C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Paul Schwichtenberg officer: SVP and CFO 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Ajay Patel officer: SVP and CAO 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Sam Schlessinger officer: SVP, General Counsel 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FORREST IL 60045
William Mckee director
Jeff L Vacirca director 4747 EXECUTIVE DRIVE, SUITE 510, SAN DIEGO CA 92121
Heather L Mason director 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
James L Tyree director 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064-6400
Crg Partners Iii - Parallel Fund (a) L.p. 10 percent owner C/O CAPITAL ROYALTY L.P., 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Mark Strobeck officer: EVP & Chief Operating Officer 460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087
Crg Partners Iii L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Cr Group L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Andrea Heslin Smiley director 600 LEE ROAD, SUITE 100, WAYNE PA 19087
Megan C. Timmins officer: SVP, Gen Csl & Sec 600 LEE ROAD, SUITE 100, WAYNE PA 19087
Crg Partners Iii - Parallel Fund B (cayman) L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002

Assertio Holdings (Assertio Holdings) Headlines

From GuruFocus